[Skip to Navigation]
Sign In
Views 691
Citations 0
Comment & Response
March 12, 2020

Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer

Author Affiliations
  • 1The Medical Department, 3D Medicines Inc, Shanghai, China
  • 2Department of Respiratory Medicine, Daping Hospital, Army Medical University, Chongqing, China
JAMA Oncol. 2020;6(5):782. doi:10.1001/jamaoncol.2020.0059

To the Editor Arrieta and colleagues1 recently published an open-label randomized clinical trial (RCT) evaluating the addition of metformin to tyrosine kinase inhibitor (TKI) treatment in nondiabetic patients with non–small cell lung cancer carrying epidermal growth factor receptor (EGFR) variants. The authors reported significantly improved survival benefits without additional toxic effects. However, there are some major issues about this work that need to be addressed, especially considering that our larger-scale placebo-controlled double-blind RCT2 attempting to answer the same question had negative results.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words